VEGF Trap-Eye Sees Positive Results in Phase 3 GALILEO Study in Patients with Macular Edema Due to CRVO

April 28, 2011

Regeneron Pharmaceuticals and Bayer HealthCare announced yesterday positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO).

In GALILEO, the primary endpoint at week 24 was achieved: 60.2 percent of patients receiving monthly VEGF Trap-Eye 2 milligrams (mg) gained at least 15 letters of vision from baseline, compared to 22.1 percent of patients receiving sham injections (p<0.0001). The key secondary endpoint of the study was also met: patients receiving VEGF Trap-Eye 2mg monthly gained, on average, 18 letters of vision compared to a mean gain of 3.3 letters with sham injections (p<0.0001).

Regeneron stated that with two Phase 3 trials now showing impressive improvement in vision relative to control, VEGF Trap-Eye has the potential to provide patients and physicians a new treatment option for central retinal vein occlusion.

Click here for the full release.




Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below